N/A
N=124
ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males
Urinary Incontinence
Bottom Line
View on ClinicalTrials.gov: NCT00277095 ↗Enrolled (actual)
124
Serious AEs
3.2%
Results posted
Feb 2016
Primary outcome: Primary: Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction. — 60.6 percentage of patients
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- ProACT (Adjustable Continence Therapy) (Device)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- Male
- Sponsor
- Uromedica
- Primary completion
- Feb 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction. |
60.6 | — |
Summary
The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 109 male patients. The ProACT device is designed to treat men who have stress urinary incontinence arising from intrinsic sphincter deficiency following an operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence.
The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether patients demonstrate at least a 50% reduction in pad weight at 18 months follow-up compared to the pad weight results at baseline.
Eligibility Criteria
Inclusion Criteria
- Undergone either a radical prostatectomy, transurethral resection of the prostate or other prostate surgery at least 12 months prior without radiation therapy
- Demonstrate primary stress urinary incontinence
- Male subjects at least 45 years of age
- Willing and able to undergo surgical implantation of the ProACT devices
- Willing and able to comply with the follow-up requirements
- Willing and able to forego any other surgical urinary incontinence treatments while participating in the study
- Willing and able to sign the informed consent
- Positive 24 hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests)
- Experiences at least 3 incontinence episodes per day during two baseline voiding diaries.
- Negative Urine culture
- No recurrent stricture at the anastamosis
- No known urogenital malignancy other than previously treated prostate cancer
- Physician determines subject to be suitable surgical candidate
Exclusion Criteria
- Primarily Urge incontinence
- Detrusor instability or over-activity
- Residual volume greater that 100 ml or greater than 25% of the total bladder capacity after voiding.
- Subject has/had or is suspected of having bladder cancer
- History of recurrent bladder stones
- Neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
- Known hemophilia or a bleeding disorder
- Abnormal PSA (Prostate Specific Antigen), according to sites laboratory standards, unless further investigation confirms no underlying prostate malignancy.
- Known sever contrast solution allergy
- Has a genitourinary mechanical prosthesis other than previous sling procedure (e.g., Artificial Urinary sphincter, implantable penile prosthesis)
- Has a urethral stricture that prevents passage of an 18 F cystoscope or has had more than one urethrotomy
- Undergone bulking procedure within 6 months of the baseline assessment
- Subject is currently enrolled or plans to enroll in another device or drug clinical trial.
- Subject is currently using an indwelling catheter or condom catheter for treatment of incontinence and is not willing to discontinue use at least 4 weeks prior to baseline assessment.
Data sourced from ClinicalTrials.gov (NCT00277095). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.